BrightEdge’s goal is to accelerate market delivery of innovative oncology treatments through capital investment, market awareness, and a shared commitment to eradicate cancer. The fund invests in for-profit companies developing novel cancer-focused treatments.
BrightEdge is investing alongside Longitude Capital, Novo Holdings, Omega Funds, Medicxi, Sofinnova Investments, venBio, F-Prime Capital, Decheng Capital, Clough Capital Partners, and Sectoral Asset Management.Ībout BrightEdge: BrightEdge, LLC is the American Cancer Society’s donor-funded, philanthropic impact fund. The capital will be used to fund clinical trials and company operations. BrightEdge’s goal is to accelerate market delivery of promising cancer-related treatments through capital investment, market awareness and a shared commitment to eradicate cancer.Ĭheckmate raised $85 million in the round led by Longitude Capital. In 2019, BrightEdge invested in Castle Biosciences (NAS: CSTL), a prognostic gene expression profile test that utilizes tumor biology to provide an individual risk of recurrence or metastasis for patients with melanoma.īrightEdge is the American Cancer Society’s donor-funded, philanthropic impact fund. This is BrightEdge’s second investment in the melanoma space. “This is strongly aligned with the American Cancer Society’s mission to save lives, celebrate lives, and lead the fight for a world without cancer.” “Checkmate has the potential to develop an immunotherapeutic focused on a population of patients with high unmet need,” said Gary Reedy, American Cancer Society chief executive officer. Checkmate is a privately held company headquartered in Cambridge, Mass. Acknowledgements This work was supported by Checkmate Pharmaceuticals. The investment is BrightEdge’s fifth since its formation in late 2018 to invest in companies developing promising cancer-related therapeutics.Ĭheckmate Pharmaceuticals’ lead product candidate, CMP-001, is an investigational cancer immunotherapeutic that has been shown to reverse resistance to anti-PD-1 therapy in some patients. Background Therapeutic options are limited for patients with advanced melanoma.
CHECKMATE THERAPEUTICS FULL
Full payment is due four weeks prior to the meeting.BrightEdge, LLC, the American Cancer Society’s philanthropic impact fund, today announced its participation in the Series C funding round of Checkmate Pharmaceuticals ( a clinical stage biopharmaceutical company focused upon activation of innate immunity to treat cancer. No-Housing packages include all costs except housing. Regular packages are all-inclusive and cover registration, food, housing, parking, a wine-and-cheese party, cocktail reception, and lobster banquet. We look forward to seeing you at Cold Spring Harbor in April. Apply in writing to Maureen Morrow stating need for financial support - preference is given to those submitting abstracts. We have applied for funds from industry to partially support graduate students and postdocs. We are eager to have as many young people as possible to attend since they are likely to benefit most from this meeting. Status (talk/poster) of abstracts will be posted on our web site as soon as decisions have been made by the organizers. Selection of material for oral and poster presentation will be made by the organizers and individual session chairs. They should contain only new and unpublished material and must be submitted electronically by the abstract deadline. Melissa Moore, University of Massachusetts Medical SchoolĪbstracts are welcomed on all scientific topics related to the development of RNA and other oligonucleotide-based therapeutic approaches. Single & Double Stranded Therapeutic Oligonucleotidesĭavid Corey, UT Southwestern Medical CenterĪdrian Krainer, Cold Spring Harbor Laboratory
We are pleased to announce the fourth Cold Spring Harbor conference on RNA and Oligonucleotide Therapeutics, which will begin at 7:30 pm on Wednesday April 8 and run through lunch on Saturday, April 11, 2015. Laura Sepp-Lorenzino, Alnylam Pharmaceuticals Bruce Sullenger, Duke University Annemieke Aartsma-Rus, Leiden University Medical Center Arthur Krieg, Checkmate Pharmaceuticals
0 kommentar(er)
